MX2009011391A - Emulsion oftalmica aceite en agua que contiene prostaglandinas. - Google Patents

Emulsion oftalmica aceite en agua que contiene prostaglandinas.

Info

Publication number
MX2009011391A
MX2009011391A MX2009011391A MX2009011391A MX2009011391A MX 2009011391 A MX2009011391 A MX 2009011391A MX 2009011391 A MX2009011391 A MX 2009011391A MX 2009011391 A MX2009011391 A MX 2009011391A MX 2009011391 A MX2009011391 A MX 2009011391A
Authority
MX
Mexico
Prior art keywords
water emulsions
emulsions containing
ophthalmic oil
containing prostaglandins
prostaglandin
Prior art date
Application number
MX2009011391A
Other languages
English (en)
Spanish (es)
Inventor
Fabio Carli
Baronian Mihran
Rene Schmid
Elisabetta Chiellini
Original Assignee
Azad Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azad Pharma Ag filed Critical Azad Pharma Ag
Publication of MX2009011391A publication Critical patent/MX2009011391A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009011391A 2007-04-24 2008-04-24 Emulsion oftalmica aceite en agua que contiene prostaglandinas. MX2009011391A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008357A EP1985298A1 (en) 2007-04-24 2007-04-24 Ophtalmic oil-in-water emulsions containing prostaglandins
US94269107P 2007-06-08 2007-06-08
PCT/EP2008/003317 WO2008128779A1 (en) 2007-04-24 2008-04-24 Ophthalmic oil-in-water emulsions containing prostaglandins

Publications (1)

Publication Number Publication Date
MX2009011391A true MX2009011391A (es) 2010-02-09

Family

ID=38924841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011391A MX2009011391A (es) 2007-04-24 2008-04-24 Emulsion oftalmica aceite en agua que contiene prostaglandinas.

Country Status (11)

Country Link
US (2) US8414904B2 (enExample)
EP (2) EP1985298A1 (enExample)
JP (1) JP5452472B2 (enExample)
CN (1) CN101674804B (enExample)
AU (1) AU2008240964B2 (enExample)
CA (1) CA2683672C (enExample)
ES (1) ES2425593T3 (enExample)
MX (1) MX2009011391A (enExample)
NZ (1) NZ579954A (enExample)
RU (1) RU2460516C2 (enExample)
WO (1) WO2008128779A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
FR2934955B1 (fr) * 2008-08-14 2011-07-08 Commissariat Energie Atomique Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2938757B1 (fr) * 2008-11-27 2010-12-31 Octalia Technologies Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation cosmetique ou dermatologique
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
AU2014250656B2 (en) * 2009-06-02 2016-05-05 Johnson & Johnson Surgical Vision, Inc. Omega-3 oil containing ophthalmic emulsions
US9480645B2 (en) * 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20100305046A1 (en) 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Stable cyclosporine containing ophthalmic emulsion for treating dry eyes
US20100303915A1 (en) * 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
KR20170095402A (ko) * 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
KR101848124B1 (ko) * 2015-03-31 2018-04-11 단국대학교 천안캠퍼스 산학협력단 타크로리무스의 경구용 과포화성 마이크로에멀젼 조성물
CN105748415B (zh) * 2016-03-18 2019-05-07 上海方予健康医药科技有限公司 一种前列地尔冻干微乳组合物及其制备方法
KR101770324B1 (ko) 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
FR3064002B1 (fr) 2017-03-14 2021-07-02 Prevor Int Melange liquide pour nettoyer les deversements de peinture, vernis, colorant et/ou lasure
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
WO2021056106A1 (en) * 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
MX2022014226A (es) * 2020-05-13 2023-04-14 Follicle Pharma Ltd Composiciones para la administracion de agentes bioactivos en foliculos pilosos.
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
KR20230124625A (ko) * 2020-12-24 2023-08-25 산텐 세이야꾸 가부시키가이샤 에피나스틴 또는 그의 염과 황계 항산화제를 함유하는경피 투여용 의약 조성물
KR20240035939A (ko) 2021-03-24 2024-03-19 글로 파마, 인크. 피부 색소침착을 감소시키기 위한 펩타이드 및 방법
ES2944784B2 (es) 2021-12-23 2025-11-24 Univ Madrid Complutense Microemulsión oftálmica, procedimiento de obtención y uso dado a la misma
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
CA2031469A1 (en) 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
ES2067864T3 (es) 1990-05-22 1995-04-01 R Tech Ueno Ltd Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
IL98747A0 (en) 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
SE518823C2 (sv) 1994-07-12 2002-11-26 Karlshamns Lipidteknik Ab Olja-i-vatten-emulsioner
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5827835A (en) 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
AU2001286210A1 (en) * 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
US7095714B2 (en) 2000-11-28 2006-08-22 Kabushiki Kaisha Toshiba Ring interconnection network system, node equipment, network management equipment, and path setting method
US20030215471A1 (en) 2001-01-31 2003-11-20 Wilmott James M. Surfactant free topical compositions and method for rapid preparation thereof
WO2002096367A2 (en) * 2001-05-30 2002-12-05 Targesome, Inc. Targeted multivalent macromolecules
KR100446960B1 (ko) * 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20040076678A1 (en) 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution
US20050228048A1 (en) 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
CA2498233C (en) 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20070286896A1 (en) * 2003-08-01 2007-12-13 National Institute Of Advanced Industrial Science And Technology Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
ES2331313T3 (es) * 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. Composicion farmaceutica que contiene prostaglandina.
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EP1827373B1 (en) 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
JP5247453B2 (ja) * 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Also Published As

Publication number Publication date
EP2136782B1 (en) 2013-06-05
CA2683672C (en) 2015-10-06
US20100112016A1 (en) 2010-05-06
HK1133598A1 (en) 2010-04-01
CA2683672A1 (en) 2008-10-30
WO2008128779A1 (en) 2008-10-30
AU2008240964B2 (en) 2013-03-07
US20130195936A1 (en) 2013-08-01
CN101674804B (zh) 2013-02-13
JP2010524992A (ja) 2010-07-22
RU2009143324A (ru) 2011-05-27
EP1985298A1 (en) 2008-10-29
NZ579954A (en) 2011-04-29
EP2136782A1 (en) 2009-12-30
CN101674804A (zh) 2010-03-17
ES2425593T3 (es) 2013-10-16
JP5452472B2 (ja) 2014-03-26
AU2008240964A1 (en) 2008-10-30
US8414904B2 (en) 2013-04-09
RU2460516C2 (ru) 2012-09-10

Similar Documents

Publication Publication Date Title
MX2009011391A (es) Emulsion oftalmica aceite en agua que contiene prostaglandinas.
BR112012014260A2 (pt) composições de iodopovidona oftalmológica não irritante
ATE493970T1 (de) Konservierungsmittelfreie augenlösung auf prostaglandin-basis
ES2529728T3 (es) Combinaciones de principios activos nematicidas que comprenden fluopiram y fluensulfone
BR112017022021A2 (pt) aplicação de agente anticaspa solúvel em tensoativo
BR112015007546A2 (pt) composições de ácido percarboxílico estáveis e usos das mesmas
WO2014081950A3 (en) Fabric care compositions comprising emulsions
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
WO2011134944A3 (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
CL2009000624A1 (es) Composicion farmaceutica oftalmica que comprende un vehiculo que incluye agua, un agente terapeutico que es una prostaglandina, un compuesto de amonio cuaternario polimerico y 0,01-04% p/v de un surfafactante que es aceite vegetal etoxilado y/o hidrogenado, libre de cloruro de benzxalconio; util para tratar glaucoma
MA32638B1 (fr) Procede de lutte contre la degradation d'ingredients actifs chimiques agricoles
CO6280437A2 (es) Una composicion de emulsion de aceite en agua que tiene una fase de agua y nua fase de aceite comprendiendo un modificador polimerico y un compuesto activo agricolamente
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
WO2015040488A3 (en) Sulfate-free structured liquid surfactants
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
PH12013502550A1 (en) Controlled release peptide formulations
CR11747A (es) Microemulsion mejorada que tiene un amplio rango de aplicacion
CL2010001620A1 (es) Composicion agricola, del cuidado personal, del cuidado de la casa y de revestimiento que comprende silicona y otro componente adicional; emulsion acuosa y no acuosa que comprende la composicion agricola; y metodo para formular dichas composiciones (div. sol. n° 656-207).
MX349169B (es) Composiciones farmaceuticas oftalmicas y metodos para elaborar y usar las mismas.
MX2019003611A (es) Formulaciones novedosas.
IN2014DN10574A (enExample)
AR054118A1 (es) Amidas de acido pirazolcarboxilico
AR049113A1 (es) Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost
CL2011003065A1 (es) Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.

Legal Events

Date Code Title Description
FG Grant or registration